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Introduction 
 
 1.1. Angiogenesis 
 
Angiogenesis is the physiological process involving vasculogenesis, intussuseption, 
bridging and/or enlargement of capillaries from pre-existing ones, whereas 
arteriogenesis means the remodeling of arteriolar anastomoses to functional arteries. 
Lymphangiogenesis is the generation of new lymphatic vessels from pre-existing 
lymphatic vessel [1]. The process of angiogenesis is involved in embryogenesis, 
growth and development, as well as in inflammation and wound healing. Additionally, 
it is also a fundamental step in tumor growth and their transition of from benign to 
malignant tumours. Small blood vessels consist exclusively of endothelial cells, lager 
vessels by contrast are surrounded by smooth muscle cells. Numerous factors such 
as vascular endothelial growth factor (VEGF), pigmeth epthelium derived factor 
(PEDF), placental growth factor (PIGF), angiopoetin (Ang) -1 and interleukin- 8 (IL-8) 
influence vascular growth.  
 
1.1.1. Angiogenesis during adipose tissue development 
 
Angiogenesis, increased number and/or size of blood vessels, is essential to supply 
growing adipose tissue with oxygen and nutrients. Adipogenesis is highly associated 
with angiogenesis in the early stages of adipose tissue development. In vitro studies 
showed that adipose tissue explants and adipocytes differentiation induce blood 
vessel formation [2,3]. Additionally in several studies it was demonstrated that 
angiogenesis inhibitors in mice have a negative impact on adipose tissue growth [4]. 
Numerous factors are involved in adipogenesis regulation in adipose tissue including 
placental growth factor (PlGF), basic fibroblast growth factor (FGF-2), angiopoetin -2 
(Ang-2), leptin, thrombospondin 1 (TSP-1), osteonectin, adiponectin, resistin, tissue 
factor (TF), tumour necrosis factor alpha (TNF-α), insulin-like growth factor (IGF), 
hepatocyte growth factor (HGF) etc. Nevertheless VEGF mRNA level is not markedly 
modulated by obesity in mice, it is expressed at a high level during adipocytes 
differentiation and in expanding adipose tissue [5] [6]. Generally it is assumed that 
the VEGF/ vascular endothelial growth factor receptor (VEGFR) system accounts for 
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most of the angiogenic activity in adipose tissue, making it an attractive target to 






Obesity is a growing worldwide metabolic disorder, because overweight persons are 
at higher risk of developing a range of diseases such as cardiovascular disorders 
(e.g. artherosclerosis), cancer, insulin resistance, hypertension and diabetes type 2 
meaning reduced life expectancy and which have a huge economic and societal 
consequences. But the exact mechanisms linking obesity to various diseases are 
poorly understood. Obesity is a medical condition in which adipose tissue mass, size 
and number of mature adipocytes is increased and is defined by the Body mass 
index (BMI) which is a value that is calculated as the body weight (kg) divided by the 
square of the height (m²) and is used as a measurement of body fat in clinical an 
epidemiological studies. The BMI values are divided into four main categories: 
underweight (BMI < 18.5 kg/m²), normal weight (BMI 18.5- 24.9 kg/m²), overweight 
(BMI 25.0- 29.9 kg/m²), obese (Class I) (BMI 30- 34.9 kg/m²), obese (Class II) (BMI 
35- 39.9 kg/m²), obese (Class III) (BMI > 40 kg/m²) (Table 1). The BMI criteria for 
Asia and Oceania are slightly different: overweight (BMI > 23 kg/m²) and obesity (BMI 




Table 1 Classifications for weight status based on Body Mass Index (BMI). 
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Figure 1 Worldwide change in prevalence of obesity in men (A) and women (B) 
between 1980 and 2008 [7].  
 
1.2.1. The growing epidemic of obesity  
In 2008, according to a study of the World Health Organisation (WHO) 1.5 billion 
adults over 20 years were overweight, 200 million of men and 300 million of women 
were obese and in 2010 about 43 million of children under 5 years were overweight 
[8] (Figure 1). Obesity is no longer just a problem of the Western industrialised world; 
the largest increases in obesity are seen in low and middle income countries [7,9]. A 
sharp increase of the total calorie intake was observed in the last decades (Figure 2). 
Commonly obesity is caused by a combination of excessive and energy-dense food 
intake, lack of physical activity and genetic susceptibility, in rare cases obesity is 
primarily caused by genes, endocrine disorders, medication or physical illness but the 
biology of obesity is very complex and not yet totally understood. Thus there is urgent 
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Figure 2 Worldwide estimates of average caloric intake in 1980 (A) and 2008 (B) [8]. 
 
1.2.2. Obesity treatment 
Dieting, physical exercise and other lifestyle modifications are mainstays in obesity 
prevention and treatment. However, epidemiological studies have shown that it is 
very difficult to loose weight and the recidivism rate for regain weight after weight loss 
is very high [10]. Anti-obesity medication is largely ineffective and associated with 
strong adverse reactions; even obesity surgery cannot prevent weight regain livelong 
[11]. Surgical therapy for obesity (bariatric surgery) can be an effective therapeutic 
modality for subjects with morbid obesity to enable substantial, clinical significant 
weight loss. Evidence shows that bariatric surgery paired with healthy food choices 
and regular exercise results in improvement or resolution of morbidities associated 
with sever obesity [12]. The International Federation for Surgery of Obesity (I.F.S.O.) 
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has developed guidelines for appropriate selection of candidates for bariatric surgery 
(Table 2). The criteria for bariatric surgery include patients with a BMI greater than 40 
kg/m² above the age/sex-defined weight. To justify bariatric surgery in subjects with a 
BMI between 35 and 40 kg/m² obesity associated comorbidities must be present and 
conservative weight management must have failed [13]. Surgical therapy for obesity 
can be classified as malabsorptive, restrictive and as a combination of the two. 
Currently the standard bariatric surgeries are Roux-en-Y gastric bypass, laparoscopic 
gastric band, biliopancreatic bypass and the sleeve gastrectomy [13].  
1.2.3. The Roux-en-Y gastric bypass 
In Europe the laparoscopic Roux-en-Y gastric bypass is the most commonly 
performed bariatric surgery.  The laparoscopic Roux-en-Y gastric bypass is a 
combination of restrictive and malabsorptive components. A small stomach pouch is 
created transecting the upper part of the stomach, next the pouch is attached to a Y-
shaped section of the small intestine bypassing the lower stomach, the duodenum 
and the first portion of the jejunum. As a result the Roux-en-Y gastric bypass restricts 
food intake and reduces the absorption of nutrients.  
 
 
Table 2 Criteria for bariatric surgery establish by the International Federation for the 
Surgery of Obesity (IFSO)  
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1.2.4. Adipose tissue and inflammation 
 
Half a century ago initial assessments pointed to the involvement of inflammation in 
obesity, including a report that described increased fibrinogen plasma level in obese 
patients [14]. The inflammatory concept attracted great interest of the scientific 
community when the enhanced expression of tumour necrosis factor alpha (TNF-α) 
in adipose tissue of obese rodents was demonstrated in the 1990s [15]. Since then 
several groups demonstrated the secretion and production of various cytokines, 
chemokines, hormones, and other inflammatory factors referred to as adipokines, 
identifying adipose tissue as one of the greatest endocrine organs in the body [16]. 
Beside TNF-α macrophage chemoattractant protein-1(MCP-1), interleukin-6 (IL-6), 
leptin, and resistin are highly expressed adipokines by obese adipose tissue and are 
suspected to be fundamental for the pathophysiology of obesity [17,18]. It is now well 
established that adipose tissue, beside its role in energy storage, also functions as 
an important endocrine organ that secretes a variety of cytokines, hormones and 
other proteins such as, interleukin-6 (IL-6), IL-8, leptin, resistin and plasminogen 
activator inhibitor-1 (PAI-1)[19] referred to as adipokines [17,18]. Obesity is causally 
linked to a low-grade inflammation state [11,14] which is involved in the development 
of obesity-linked disorders, in particular metabolic dysfunctions. Excess adiposity and 
adipocytes dysfunction engender an unregulated expression and secretion of 
adipokines which has been linked to the development of various disease processes 
through altered immune response (Figure 3). According to this there is considerable 
interest to develop a better understanding of the immunoregulatory function of 
adipose tissue. Adipokines have been identified to either contribute to the resolution 
of inflammation or promote inflammatory response and metabolic dysfunction. 
Therefore it is assumed that an imbalance of pro- and anti-inflammatory adipokines 
secreted by adipocytes entail metabolic dysfunctions. Lately much attention has been 
paid to developing a better understanding of the immunoregulatory function of 
adipocytes and adipose tissue. New adipokines have been identified to either cause 
inflammatory responses and metabolic dysfunction or contribute to the removal of 
inflammation and have positive effects on obesity linked disorders [20]. These 
insights suggest that an imbalance of pro- and anti-inflammatory adipokines 
contributes to the development of metabolic dysfunction. 














Figure 3 Linkage between metabolism and immunity [21]. 
 
1.2.5. Categories of adipose tissue 
Adipose tissue can be categorized in three different categories: lean with normal 
metabolic function, obese with light metabolic dysfunction and obese with complete 
metabolic dysfunction. As adipose tissue growths, adipocytes undergo hypertrophy 
increasing their triglyceride storage. With mild obesity, adipose tissue maintains 
relatively normal metabolic function, low levels of immune cell activation and 
sufficient vascular function. However, expansion of adipose tissue promotes the 
transition to a metabolically dysfunctional phenotype. M2 type macrophages are 
mainly found in lean adipose tissue, whereas in states of obesity adipose tissue M1 
macrophages and T cells are accumulated. Anti-inflammatory adipokines are mainly 
produced by lean adipose tissue; a great number of proinflammatory factors are 
secreted by adipose tissue in obese patients [22]. 
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Figure 4 Phenotypic modulation of adipose tissue [22]. 
 
1.2.6. Clinical observations 
 
Especially increased visceral fatty tissue (Figure 4) in obese patients leads to a 
chronic low grade inflammatory state [14,15] which has a crucial role in pathogenesis 
of obesity-induced disorders. Excess adiposity - in particular visceral adiposity- and 
adipocytes dysfunction result in deregulated expression of adipokines and has been 
linked to development of various diseases processes through varied immune 
response. Clinical and epidemiological studies have described a considerably 
connection between the development of low grad inflammation and metabolic 
diseases, especially in the field of obesity and type 2 diabetes. Obese individuals 
demonstrate an increased level of the pro-inflammatory marker C- reactive protein 
(CRP) in the blood [23].  An increased CRP and IL-6 level is a sign for the 
development of type 2 diabetes in various populations [16,17]. In addition weight loss 





  9 
 
 
Figure 5 Components of adipose tissue [22]. 
 
1.2.7. The adipokine concept 
 
Adipose tissue is a very complex and highly active metabolic and endocrine organ. 
Besides adipocytes, adipose tissue contains preadipocytes, fibroblasts, nerve tissue, 
immune cells, connective tissue and vascular cells (Figure 5). as described above 
adipose tissue was originally considered as an energy storage organ but it was 
recently detected that it also expresses and secretes factors with important endocrine 
functions the so-called adipokines [17,18]. Following the onset of obesity, the cellular 
composition of adipose tissue can be modified including changes in localization, 
number an phenotype of cells resulting in a difference of the adipokine secretion 
status. The expression pattern of adipokines is depended on the site of the adipose 
tissue depot. Visceral and subcutaneous adipose tissue represent the most important 
fat depot and produce a different adipokine composition [25,26] (Figure 6). A recent 
study showed that subcutaneous adipose tissue has significant higher mRNA 
expression of leptin, TNF-α and NFκB. In contrast visceral adipose tissue has higher 
expression of complement factor C3. No differences were observed for the 
expression of IL-8 and IL-1β [25]. 
 















Figure 6 Adipose tissue depots in human body [22]. 
 
1.3. Biology of the pigment epithelium-derived factor (PEDF)  
 
The pigment epithelium-derived factor (PEDF), member of the serpins (serin 
protease inhibitors), is a non-inhibitory, multifunctional protein with neurotrophic, 
antiangiogenic, antitumorigenic, anti-inflammatory, antioxidant and antithrombic 
properties [27,28]. The glycoprotein PEDF was initially detected by Joycs Tombran-
Tink and Lincoln Johnsonn in conditioned medium from fetal human retinal pigment 
epithelium (RPE) cells as a factor with effective neuronal differentiation property [29].  
 
1.3.1. Human PEDF gene and protein 
 
The human PEDF is encoded by the 15.6kb SERPINF1 gene [30], which is localized 
on chromosome 17p13.1. The SERPINF1 gene is composed of 8 exons and 7 
introns [31]. A 200bp promoter is localized upstream of the PEDF gene which is the 
suggested binding site for the transcription factors HNF4, CHOP and USF [32]. PEDF 
is a single chain protein, consisting of 418 amino acid residues, it reveals a high 
proportion of structural homology comparing the amino acid sequences with other 
serin protease inhibitors [30]. However, it does not display any protease inhibitor 
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features [33]. PEDF is not exclusively expressed in the eye but in various tissues 
such as the spinal cord, brain, skeletal muscles [34], adipose tissue [35], bone [36], 
heart [37] and liver [38] and  also in human plasma high concentrations of PEDF 
were found. Although  PEDF is expressed in many tissues, it has no influence on 
viability as PEDF null mice are viable and fertile [39]. Investigating which cells 
express PEDF retinal pigment epithelial cells [29], hepatocytes [40,41] , Müller cells 
[42], smooth muscle cells macrophages [42,43] , various tumor cells [43], cardic 
myocytes and fibroblasts [44] and adipose tissue [45] have so far been described as 
cellular source of PEDF. Famulla et al. identified adipocytes as the main source of 
PEDF, moreover they demonstrated that increasing PEDF protein expression and 
secretion positively correlates with the differentiation stage of adipocytes [45]. 
Furthermore two other studies found a connection between human obesity and PEDF 
plasma concentration, suggesting adipocytes as the main source of PEDF [46,47].  
The human SERPINF1 gene encodes for a 418 amino acids peptide with a molecular 
weight of 50 kDa, secreted as a monomeric glycoprotein [48]. The N-terminus of the 
PEDF protein contains a leader sequence (residues 1-19) inducing protein secretion 
out of the cell [49]. Two PEDF epitopes with distinct functions were identified: the 34 
amino acid peptide (residues 24-57) acts on endothelial cells, induces apoptosis and 
thereby has antiangiogenic properties; a 44 amino acid peptide (residues 58-101) is 
suggested to be responsible for the neurotrophic properties of PEDF [49].  The 34 
amino acid epitope binds the non-integrin 37/67 kDa laminin receptor procuring the 
PEDF induced inhibition of angiogenesis [50]. Additionally the 80 kDa phospholipase-
linked membrane protein independent phospholipase A2 (PLA2)/ adipose triglyceride 
lipase (ATGL) was identified as a PEDF receptor. The enzymatic activity of the 
receptor is stimulated by binding PEDF whereby survival and differentiation of 
neurons is promoted through inducing lipid metabolism on neuronal surfaces [51]. 
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1.3.2. Crystal structure of PEDF 
 
Simonovic et al. solved the crystal structure of human glycosylated PEDF. The three-
dimensional structure includes 3 beta sheets and 10 alpha helices. (Figure 7) 
Furthermore the structure reveals a noteworthy asymmetric charge distribution with a 
high density of acid residues concentrated on the one site of the molecule and basic 
residues on the opposite side resulting in a polar 3D structure. The heparin- and 



















Figure 7 Stereoscopic model of glycosylated PEDF [52]; α-Helices are shown in 
magenta (hA, hD-F, hl), strands of β-sheets are shown in cyan (sA-C), NAG are 
represented as ball-and-sticks. The reactive center loop is labeled as RCL, and N-
acetylglucosamine is labeled as NAG. 
 
1.3.3. PEDF as an antiangiogenic factor 
 
As mentioned above PEDF is a multifunctional pleiotropic protein with antiangiogenic, 
antitumorigenic, anti-inflammatory, antioxidant and antithrombic properties [27,28] 
and has a widespread expression throughout various human tissues such as the 
adipose tissue, liver, bone, skeletal muscle and plasma. PEDF is a protein with 
strong antiangiogenic features; it has a stronger antiangiogenic impact than other 
antiangiogenic factors such as thrombospondin, angiostatin or endostatin [43].  
PEDF oppresses ischemia-induced angiogenesis and VEGF- and basic (b) FGF- 
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induced migration and proliferation of endothelial cells [53]. Additionally PEDF inhibits 
angiogenesis interacting with vascular endothelial growth factor VEGF signalling [53-
55]. Various findings suggest that the antiangiogenic activity of PEDF is interceded 
via two different mechanisms; via the onset of apoptosis in endothelial cells and via 
disturbence of the pro- and antiangiogenic factors balance.  
PEDF induces apoptosis exclusively in activated endothelial cells of newly formed 
vessels but not in pre-existing vessels by activating the FAS-FAS ligand death 
pathway. Activated endothelial cells under the influence of pro-angiogenic factors 
solely express the FAS receptor and are sensitized toward Fas-mediated apoptosis. 
Endothelial cells stimulated with PEDF display increased FASL expression leading to 
caspase-dependent induction of apoptosis [56]. In cultured endothelial cells PEDF 
induces apoptosis by activating p38 MAPK-dependent cleavage of caspase 3, 8 and 
9 [57] and by sequential induction of PPAR and p53 [58]. Furthermore PEDF 
counteracts the effect of VEGF enhancing the cleavage of VEGF receptor 1 by the 
gamma secretase, resulting in inhibition of VEGF-induced angiogenesis [59]. There is 
convincing evidence that the expression of PEDF is regulated by hypoxia. Under 
anoxic conditions mRNA and protein expression was reduced up to 50 % in human 
cardial fibroblasts and myocytes [44]. As a consequence of low oxygen concentration 
the hypoxia-inducible transcription factor (HIF) is stabilized and transported into the 
nucleus [60]. Under hypoxic conditions PEDF production decreased in 
retinoblastoma and retinal pigment epithelium cells, but solely at the protein level and 
not at the mRNA level [43,61]. Notari et al suggested that PEDF is a substrate for 
matrix metalloproteinase (MMPs), MMP-2 and -9, which are hypoxia-activated and by 
proteolytically degrading of PEDF influence its posttranslational regulation [61]. Many 
indications suggest that the expression of the proangiogenic factor VEGF is 
upregulated under hypoxic conditions [60]. As well as in human cardiac fibroblasts 
and myocytes as in the retina and retinoblastoma cells anoxic conditions not only 
result in increased expression of the proangiogenic factor VEGF but also in decrease 
of antiangiogenic PEDF expression [43,44]. 
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1.3.4. PEDF as an antioxidant, antithrombotic and anti-inflammatory factor 
 
Recently it became evident that PEDF protects endothelial cell against inflammatory 
activation and injury, which is pivotal for the development of atherosclerosis, by 
inhibiting TNF alpha induced IL-6 expression via suppression of reactive oxygen 
species (ROS) generation by NADPH oxygenase  [62,63]. Recently Park et al. 
identified PEDF as an endogenous inhibitor of the canonical Wnt pathway [64] 
[Figure 8]. The canonical Wnt signalling pathway is a highly conserved pathway. The 
intracellular signalling cascade is initiated by the binding of a Wnt ligand to the 
coreceptor complex consisting of the Frizzled (Fz) receptor and the low-density 
lipoprotein receptor related protein 5 (LRP5) or LRP6, causing the activation of the 
Dishevelled (Dsh) protein. The activated Dsh inhibits a second complex of proteins 
that includes axin, glycogen synthase kinase 3 (GSK-3), and the protein 
adenomatous polyposis coli (APC). The axin/GSK-3/APC complex normally promotes 
the proteolytic degradation of the β-catenin intracellular signalling molecule. After this 
the GSK-3 is no longer able to phosphorilate β-catenin, releasing it for the 
axin/GSK3/APC complex and leading to β-catenin accumulation and migration to the 
nucleus. The nuclear β-catenin interacts with the T-cell factor (TCF) and thereby the 
transcription factors of multiple target genes including genes relevant for 
angiogenesis, inflammation and fibrosis are activated. PEDF inhibits the Wnt/ β-
catenin pathway by binding to the LRP6, a Wnt coreceptor, with high affinity and in 
this way blocks the Wnt signalling induced by Wnt ligand [64]. Additionally it was 
observed that PEDF plays a causal role in evolution of insulin resistance [45].  
 



























Figure 8 A model of the Wnt activation of the β-catenin signalling pathway. 
(Molecular Biology of the Cell, 4th edition, Bruce Alberts). 
 
 
1.4. Vascular endothelial growth factor (VEGF) 
 
The vascular endothelial growth factor (VEGF) family represents important signaling 
molecules, involved in the modulation of various pathophysiological processes in the 
vasculature. They regulate vasculogenesis during embryonic development and 
angiogenesis and vascular maintenance in adults. VEGFs are involved in 
cardiovascular biology, tissue regeneration, ovarian angiogenesis, endochondrial 
ossification, survival of haematopoetic stem cells and erythropoietin regulation and 
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1.4.1. Biology of the VEGF family 
 
The VEGF gene family consists of numerous members including VEGF-A, -B, -C, -D, 
-E, -F and PlGF (placental growth factor) (Figure 9). In 1989 VEGF-A (also called 
VEGF) was the first VEGF family member to be discovered, subsequently four other 
members of the human VEGF family (VEGF -B, -C, -D and PlGF) have been 
identified [68,69]. Additionally viral VEGF homologues called VEGF-E and snake 
venom VEGFs (VEGF-F) have been detected [70,71]. VEGF is a homodimeric 
glycoprotein consisting of two identical 23kDa subunits [67]. All members of the 
VEGF family regulate downstream signaling by binding to 3 different tyrosine kinase 
receptors (VEGF receptor, VEGFR 1-3) on cell surface, causing them to dimerize 
and become activated through transphosphorylation [72]. Neuropilin-1 (NRP1) is a 














Figure 9 The VEGF family and its receptors [67]. 
 
1.4.2. Expression and regulation of VEGF 
 
VEGF in adults is expressed in every vascularised tissue particularly in large blood 
vessels in skeletal muscle, fenestrated and sinusoidal blood vessels and in secretory 
and endocrine organs. Therefore low physiological VEGF level is assumed to be 
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essential for the maintenance of vascular homeostasis [74].  Much higher levels of 
VEGF are crucial for vasculogenesis and angiogenic mechanisms [72]. VEGF is a 
central stimulator of angiogenesis, its binding to VEGF receptors promotes 
endothelial cell migration and proliferation, two key features required for 
angiogenesis [75]. 
Expression, availability and activity of VEGF is strictly regulated through a large 
number of stimuli and by diverse mechanisms such as hypoxia, transcription factors, 
oncogenes, inflammatory cytokines, mechanical forces and cell stretch [66]. Hypoxia 
stimulates the secretion of VEGF via up-regulation of hypoxia inducible factor-1 α 
(HIF-1α) [76,77]. Numerous growth factors and cytokines such as TNF-α, IL-6, IL-1, 
platelet-derived growth factor-BB (PDGF-BB), PlGF, HGF, TGF-β, FGF, IGF-1 up-
regulate VEGF-A expression [76,78]. Under normal conditions VEGF synthesis is 
regulated by the Hippel-Landau tumor suppressor protein, which under normal 
conditions ubiquitinates the most important transcriptional activators HIF-1α and 





The chemokine IL-8  is a member of the CXC chemokine subfamily and is encoded 
by the IL-8 gene, located on chromosome 4q13–q21 in humans, composed of four 
exons, three introns, and a promoter region [81]. The chemokine is secreted by 
several cell types such as macrophages, epithelial cells and endothelial cells; 
endothelial cells store IL-8 in the Weible-Plade bodies [82]. IL-8 is expressed in 
numerous normal and tumor cells and its main function is to initiate and amplify acute 
inflammatory reactions [83]. There is increasing evidence that IL-8 plays an important 
role in the pathogenesis of cancer by modulating angiogenesis, tumor growth, and 
metastasis [84-88]. One of the pivotal roles of IL-8 is the induction of chemotaxis in 
neutrophiles and lymphocytes but many different cell types (macrophages, mast 
cells, keratinocytes and endothelial cells) also respond to the chemokine [89,90]. IL-8 
binds to the high- affinity receptors CXCR1 and CXCR2 belonging to CXC chemokine 
receptors, a large family of G protein-linked receptors, capable of inducing 
angiogenic behavior in endothelial cells [91,92]. A great number of molecular 
pathways are involved in the IL-8-induced angiogenic behavioral responses in ECs 
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(e.g., survival, migration, generation of a branching morphogenesis and proliferation 
of EC) and are relatively unexplored. Mechanisms involved in IL-8 mediated 
angiogenesis include activation of MMPs and differential expression of antiapoptotic 
genes [93], Rac-dependent cell retraction and gap formation [94], RhoA-dependent 
gap formation, CXCR2-mediated VEGFR transactivation [95] and EGFR 
transactivation [94]. Recently it has been shown that PEDF downregulates IL-8 
production in hormone-refractory prostate cancer cells (HRPC) through inactivation of 




Figure 10 Model established by Hirsch et al for PEDF signaling in human hormone-
refractory prostate cancer cells (HRPC). In HRPC, NFκB transcription factor up-
regulates IL8 expression (Left panel). IL8 binds the CXCR2 receptor and induces 
proliferation of HRPC. PEDF interacts with PEDFR and up-regulates PPARγ (Right 
panel). PPARγ inhibits transcriptional activity of NFκB resulting in repressed IL8 
expression and reduced cell proliferation [96]. 
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1.6. Aims of the project 
 
The aim of the study was to investigate the regulation and autokrine function of PEDF 
in human visceral and subcutaneous preadipocytes/adipocytes and to determine the 
parakrine effects on cells that are involved in angiogenesis such as HCASMC and 
HUVEC. Recently it has been demonstrated that PEDF is massively expressed in 
human adipose tissue and increases during adipogenesis [45]. The aim of this 
project was to comprehend the significance of PEDF for angiogenesis and adipositas 
progression in more detail. Further studies could lead to a new and effective therapy 
which blocks the progression of adiposity.  The aims of the present project consist of 
several parts as follows:  
 
Part I: The aim of this project was to investigate a possible role of PEDF in obesity. In 
a first step we studied the regulation of the expression of PEDF in human visceral 
and subcutaneous preadipocytes and adipocytes isolated out of adipose tissue. 
Part II: As obesity is associated with a generalized inflammatory state we tested 
whether inflammatory mediators affect the expression of PEDF in preadipocytes and 
adipocytes.  
Part III: Considering that adipose tissue in vivo is always exposed to an inflammatory 
hypoxic milieu and as anoxia is a critical modulator in various organs and tissues 
modulating angiogenesis we studied a possible influence of anoxia on the expression 
of PEDF in preadipocytes, adipocytes and adipose tissue.  
Part IV: In a further step, we investigated whether the stimulation of human coronary 
artery smooth muscle cells (HCASMC) with PEDF (400ng/ml) affects the expression 
and protein level of VEGF.  
Part V: It has been shown that PEDF downregulates IL-8 production in hormone-
refractory prostate cancer cells (HRPC) through PEDF receptor/phospholipase A2 
induced inactivation of NF-κB and up-regulation of PPARγ The third aim of the 
project was to study a possible effect of PEDF on IL-8 mRNA expression and protein 
production in HUVEC. 
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1. Materials and Methods 
 
1.1. Cell culture 
2.1.1. Standard growth conditions  
All cell lines were grown in 75 cm² and 225cm² tissue culture flasks (Iwaki) or in 24 
well cell-culture plates in a humidified incubator (Thermo Scientific Heraeus 
Cytoperm 2) under the conditions of 37°C and 5% CO 2. 24-well-plates were obtained 
from Greiner Bio One. 
2.1.2. Splitting and cell counting  
For cell splitting, medium was aspirated and cells were shortly washed with PBS 
without Ca and Mg. Cells were then incubated for 2 to 6 minutes with trypsin at 37°C 
and resuspended in the appropriate medium. Cells were spun down for 5 minutes at 
1500 rpm. The resulting cell pellet was resuspended in the appropriate medium. Cell 
concentrations were determined with a Neubauer counting chamber.   
2.1.3. Isolation and cultivation of human preadipocytes  
Visceral and subcutaneous adipose tissue was obtained from patients undergoing a 
laparoscopic Roux-en-Y gastric bypass surgery. All subjects were of Caucasian 
origin and did not suffer from acute acute infection, cancer or any other consuming 
disease. All human material was obtained and processed according to the 
recommendations of the hospital’s Ethics Committee and Security Board, which 
included obtaining informed consent.  
Primary cultures of human preadipocytes were prepared from adipose tissue of 
subcutaneous and visceral origin obtained as described above. Tissue was dissected 
from skin, visible blood vessels, and fibrous material, minced into small pieces (1 to 2 
mm), and digested in Hanks’ balanced salt solution containing 0.1% collagenase type 
IV (both from Sigma) for 60 minutes at 37°C in a shaking incubator (WTB Binder 
BFED-53). After they were filtered through a 70-µm nylon mesh (BD Falcon), cells 
were centrifuged for 10 minutes at 1000 rpm, washed once with DMEM/F-12 
containing 20% fetal calf serum (Biochrom), passed through a 40-µm nylon mesh (BD 
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Falcon), and centrifuged for 5 minutes at 1500 rpm. The isolated sedimented cell 
fraction was incubated with erythrocyte lysis buffer containing 154 mmol/L NH4Cl, 10 
mmol/L KHCO3, and 0.1 mmol/L EDTA (all from Merck) for 10 minutes at room 
temperature. After centrifugation for 5 minutes at 1500 rpm the resulting cell pellet 
was resuspended in DMEM/F-12 containing 20% fetal calf serum. Cell concentration 
was determined with a Neubauer counting chamber and cells were seeded into 24-
well plates. All cells were grown in a humidified incubator (Thermo Scientific Heraeus 
Cytoperm2) under the conditions of 37°C and 5% CO2.  After cell adhesion for 24 
hours, preadipocytes exhibited the characteristic fibroblast like shape (Figure 11). 
Medium was replaced every other day.   
2.1.4. Adipocyte differentiation  
After adhesion of preadipocytes for 24 hours, adipose differentiation was induced 
with serum-free DMEM/F-12 containing 33 µmol/L biotin, 17 µmol/L pantothenate, 1 
nmol/L triiodothyronine, 100 nmol/L dexamethasone, 500 nmol/L insulin, 1 µmol/L 
pioglitazone, and 0.25 µmol/L isobutyl-methylxanthine, for the first 3 days, (all from 
Sigma). Half of the medium was replaced every other day; differentiation was verified 
by staining with Sudan III, in which differentiated adipocytes were defined as cells 
whose cytoplasm was filled completely with lipid droplets (Figure 12). Only cultures 
with >90% adipocytes were used for further adipocyte experiments. All cell culture 
media and buffers contained 100 U/mL penicillin, 100 U/mL streptomycin, 0.25 µg/mL 


























Figure 12 Phase contrast micrographs of human subcutaneous adipocytes. 
2.1.5. Principles of adipocyte differentiation  
Committed preadipocytes undergo growth arrest and consequently terminal 
differentiation into adipocytes, which is associated with an increase in expression of 
adipocytes genes, lipid- metabolizing protein and adipocyte fatty acid binding protein. 
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During the growth phase, preadipocytes are morphologically similar to fibroblasts, 
when they are treated with a combination of isobutyl-methylxanthine (IBMX), 
dexamethasone and insulin, cells undergo a drastic cell shape change, start to adopt 
a rounded phenotype. Within 4-8 days preadipocytes begin to accumulate lipids in 
form of intracellular lipid droplets and subsequently acquire the morphological and 
biochemical characteristics of mature white adipocytes. Treatment of cells with 
dexamethasone activates CCAAT/enhancer-binding protein β (C/EBPβ) transcription 
factor, which plays a key role in the complex transcriptional cascade of adipocyte 
differentiation. IBMX inhibits soluble cyclic nucleotide phosphodiesterases, resulting 
in increased intracellular cyclic adenosine monophosphate (cAMP) levels. At the 
nuclear level, treatment with IBMX results in activation of the transcription factor 
C/EBP δ which induces transcription of C/EBP α and peroxisome proliferator-
activated receptor-γ (PPAR-γ). C/EBPα, β and δ are members of a transcription 
factors family that interact with the CCAAT (cytidine-cytidine-adenosine-adenosine-
thymidine) box motif, which occurs in several gene promoters [97]. PPAR-γ is a 
ligand-activated transcription factor which shares structural homology with the 
nuclear hormone receptor superfamily. PPARs induced transcriptional regulation 
requires heterodimerization with the retinoid X receptor (RXR). When activated by a 
ligand, the dimer increases transcription by binding to specific DNA sequence 
elements called peroxisome proliferator response element (PPRE) in the promoter 
region of target genes [98]. Within 3 days of exposure to inducers, the cells undergo 
two rounds of mitosis, and then mitotic clonal expansion is termed, which is required 
for differentiation. Insulin or insulin-like growth factor-1 promotes adipocyte 
differentiation by activating PI3-kinase and Akt activity. Modulation of the activity of 
the forkhead transcription factor Foxo1 appears to be necessary for insulin to 
promote adipocyte differentiation. C/EBP α and PPAR direct the final phase of 
adipogenesis by activating expression of adipocyte-specific genes, such as fatty acid 
synthetase, fatty acid binding protein, leptin and adiponectin. Biotin is a coenzyme in 
the metabolism of fatty acids and leucine, and it plays a role in gluconeogenesis [99]. 
Pantothenic acid is an essential nutrient required to synthesize coenzyme-A (CoA), 
as well as to synthesize and metabolize proteins, carbohydrates, and fats [100]. 
Triiodothyronine increases the production of the Na+/K+-ATPase and, in general, 
increases the turnover of different endogenous macromolecules by increasing their 
synthesis and degradation [101]. Pioglitazone stimulates the nuclear receptor 
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peroxisome proliferator-activated receptor gamma (PPAR-γ) and to a lesser extent 
PPAR-α. It modulates transcription of insulin-sensitive genes involved in lipid 
metabolism control in adipose tissue, muscle and liver [102]. 
2.1.6. Staining of human adipocytes with Sudan III 
Saturated (approximately 1%) stock solution of oil red O in 99% isopropanol was 
prepared. 60 ml of stock solution was diluted with 40 ml 1% dextrin. Solution was left 
to stand over night and then filtered.  
Adipocytes were washed 3 times with PBS. Then cells were fixed with 7.5% 
formaldehyde for 30 min, after that cells were again washed 3 times with PBS and 3 
times with 50% ethanol. Thereafter cells were stained for 40 min with Sudan III 
solution and washed three times with 50% ethanol and washed two times with tap 













  26 
2.1.7. Stimulation of human preadipocytes and adipocytes 
Preadipocytes and adipocytes were incubated in serum-free DMEM/F-12 for 24 hours 
before treatment with the cytokines. Thereafter, the medium was replaced with fresh 
DMEM/F-12 and recombinant human (rh) OSM (R&D Systems), rhIL-6 (Invitrogen), 
rhIL-8 (Invirtogen), TNF-α (R&D Systems), SFRP5 (R&D Systems), rhIL-10 
(Invitorgen), rhIL-4 (R&D Systems), rhIL-18 (Invitorgen), rhIL-33 (Biovison), rh-Leptin 
(Prospec) was added at the concentrations indicated. After incubation for 4, 24 and 
48h culture supernatants were collected and used immediately or stored at –20°C. 
Cells were lysed for mRNA isolation. 
 
Table 3 Used cytokines and concentrations for stimulation of primary HVPAC, HVAC, 
HSPAC and HVAC. 
2.2. Isolation and cultivation of human coronary artery smooth muscle cells 
(HCASMC) 
Human coronary artery smooth muscle cells (HCASMC) (Figure 14) were derived 
from tunica intima and tunica media of normal coronary arteries, obtained from 
patients undergoing heart transplantation. HCASMC were isolated by explant 
techniqueas described below. Human coronary artery was cut in small pieces and 
placed on a petri dish coated with 1% gelatine. Tissue pieces were covered with  
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minimal essential medium ( M199; Sigma) containing 20% fetal calf serum (FCS), 20 
ng/ml endothelial cell growth supplement (ECGS), 100 U/ml penicillin, 100U/ ml 
streptomycin, 0,25µg/ml fungizone and 2 mM L-gluatin (all Cambrex) and incubated 
at 37°C in a humidified atmosphere of 5% CO²: 95% a ir for one to four weeks. After 
cell attachment the pieces were removed. Cells were cultured in cell culture flasks 
coated with 1% gelatine in M199 containing 20% FCS 100 U/ml penicillin, 100U/ ml 
streptomycin, 0,25µg/ml fungizone and 2 mM L-glutamin at 37°C in humidified 
atmosphere of 5% CO²:95% air. Cells were used at low passages. For anoxia 
experiments cells were cultivated in Anaerocult® IS special incubation bags (Merck). 
2.2.1. Stimulation of human coronary artery smooth muscle cells (HCASMC) 
24 hours (h) before treatment with the respective cytokine HCASMC were incubated 
in M199 containing 0.1% bovine serum albumin (BSA; Sigma). Thereafter medium 
was replaced with fresh M199 containing 0.1% BSA and recombinant human PEDF 
obtained from Millipore (Bedford) at the indicated concentrations for time periods 
between 4h and 72h. For anoxia experiments cells were cultivated in Anaerocult® IS 
special incubation bags (Merck). 
 
Figure 14 Phase contrast micrographs of human coronary artery smooth muscle cells 
(HCASMC). 
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2.3. Isolation and cultivation of human umbilical vein endothelial cells (HUVEC) 
HUVECs (Figure 15) were isolated from normal human umbilical cords. An adaptor 
was inserted into the lumen of umbilical cord vessel vein and fixed with sterilized 
cable-binder. A 20ml-syringe filled with HBSS (Sigma) was connected to the adaptor 
and the vessel was flushed with 20ml HBSS. Another syringe filled with collagenase 
solution was connected to the adaptor. The vessel was slowly filled with collagenase 
solution (collagenase type IV (Sigma), 2mg/ml in HBSS modified) until it leaked out at 
the other end of the vessel, then the other end of the vessel was closed with a 
haemostat and filling of the vessel was continued. The umbilical cord vessel was 
incubated 50 minutes at room temperature; the haemostat was opened after placing 
the vessel over a centrifuge tube to collect the perfusate. The vessel was flushed with 
20ml HBSS, which was and added it to the perfusate. This was then centrifuged for 5 
minutes at 1500 rpm. The supernatant was carefully discarded and the pellet was 
resuspended in M199 (Sigma) containing antibiotics, 20% FCS, 5U/ml heparin, 
5µg/ml endothelial cell growth supplement ECGS. Resuspended cells were 
transferred into an appropriate tissue culture flask, coated with 1% Gelatine and 
incubated at 37°C, 5% CO 2. Medium was changed after 24 hours. 
2.3.1. Stimulation of human umbilical vein endothelial cells (HUVEC) 
For stimulation M199 containing 20% FCS was replaced with fresh M199 containing 
1.25% FCS and recombinant human PEDF obtained from Millipore (Bedford) at the 
indicated concentrations for time periods between 4h and 72h. For anoxia 
experiments cells were cultivated in Anaerocult® IS special incubation bags (Merck). 
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Figure 15 Phase contrast micrographs of human umbilical vein endothelial cells 
(HUVEC). 
2.4. RNA analysis 
2.4.1. mRNA purification and determination of RNA concentration 
Cells were stimulated as described above, supernatant was removed, and mRNA 
was isolated with the High Pure RNA Isolation Kit (Roche) according to the 
manufacturer’s instructions. Briefly cells were lysed with a mixture of lysis/binding 
buffer and PBS. The entire sample was pipetted into the High Pure filter tube and 
centrifuged. The filter tube was removed from the collection tube, the flow-through 
was discarded and the filter tube was again combined with the collection tube. The 
samples were incubated for 15 min at RT with a mixture of DNAse incubation buffer 
and DNAse I working solution, thereafter samples were washed once with wash 
buffer I and twice with wash buffer II always followed by centrifugation after each 
washing step. After the last washing step the filter tube was removed from the 
Collection tube, combined to a nuclease free, sterile microcentrifungation tube and 
elution buffer was added. The tube was centrifuged for 1 min at 8000 rpm, afterwards 
the filter was removed and the RNA containing tube was stored at -80°C. For 
determination of RNA concentration, 1µl of each RNA sample was examined on the 
NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific). 
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2.4.2. Synthesis of complementary DNA by reverse transcription 
mRNA was transcribed into cDNA using the Transcriptor First Strand cDNA 
Synthesis Kit (Roche, Basel, Switzerland). After determination of RNA concentration, 
the appropriate volume for 1µg of RNA was calculated. The RNA was prepared in 
Eppendorf cups and filled up with nuclease-free water to 10 µl. 2.0µl Random 
Hexamer Primer and 1.0µl Anchored-oligo(dT)18 Primer  were added per sample 
and incubated 10 min at 65°C for annealing. Masterm ix was prepared according to 
Table 4 and was then added to the RNA samples and the program (10 minutes on 




Table 4 Mastermix for cDNA synthesis 
 
2.4.3. Quantitative Real-Time PCR 
The general principle of a hydrolysis probe assay (Figure 16) is basically the same as 
for standard PCR: cDNA is denaturated, annealed with primers and a desired 
fragment within the gene of interest is amplified. In addition, real-time PCR exactly 
quantifies the amount of PCR product in real time, simultaneously to the 
amplification. This is possible by addition of a short nucleotide probe labelled with a 
fluorescent reporter as well as a quencher. The 3´-end of the probe is 
phosphorylated, so that it can not be extended during PCR. When the probe is intact 
the quencher molecule is close enough to the reporter to suppress the reporter 
fluorescent signal. As the primers bind and are extended 5´- nuclease activity of the 
Taq polymerase cleaves the hydrolysis probe and reporter and quencher are 
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released separately. In the cleaved probe the dye is able to emit fluorescence, 
correlating to the amount of PCR product. Consequently, the total amount of PCR 
product can be measured at every time point during the process. Upon comparison 
with a housekeeping gene e.g. human glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) the exact amount of the gene of interest expressed in the cell population 
can be determined.   
 
Figure 16 Mechanism of hydrolysis probe assay (Roche) 
Specific mRNA levels for PEDF VEGF IL-8 and GAPDH were determined by real 
time PCR. Samples were analyzed in triplicates on a 96-well reaction plate (Roche, 
Basel, Switzerland) applying the real-time LightCycler Probe Master, LightCycler 
TaqMan Master UniversalProbeLibrary kit (Table 5). Real-time polymerase chain 
reaction (PCR) was performed with the LightCycler 480 Real-Time PCR. Primers, 
shown in Table 6, were designed using the Roche Universal ProbeLibrary Assay 
Design Centre (http://www.universalprobelibrary.com). Thermal program shown in 
Table 7 was used. The amplification conditions consisted of an initial incubation at 
95°C for 10 minutes, followed by 70 cycles of 95°C for 10 seconds, the respective 
annealing temperature of 60°C for 20 seconds and 72 °C for 20 seconds and a final 
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cooling to 40°C. Data was analyzed using LightCycle r 480 Software Version 1.5 
Service Pack 3 (Roche). 
 
 
Table 5 Real-time PCR master mix 
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Table 7 Thermal cycling program for qRT-PCR 
 
2.5. Antigen assays 
2.5.1. Enzyme-linked immunosorbent assays 
IL8 and VEGF-A antigen in culture supernatants were measured by enzyme-linked 
immunosorbent assay (ELISA) using monoclonal antibodies against human VEGF-A 
(Quantikine Immunoassay; eBioscience.) and human IL8 (Quantikine ELISA kit; R&D 
Systems), respectively. All measurements were performed in triplicates.  
2.5.2. VEGF ELISA 
VEGF antigen was determined by a specific ELISA (Figure 17) with a standard range 
from 15.6 to 1000 pg/ml according to manufacturer’s instructions. In short the pre-
coated microwell strips were washed twice with wash buffer. Samples and standards 
were properly diluted with sample diluent, added to the wells and incubated at room 
temperature for 2 hours, on a microplate shaker set at 100 rpm. Test wells were 
empted and the plate was washed, the VEGF conjugate was added to the wells, 
incubated for 2 hour. Following a washing step substrate solution for colour 
development was applied for 20 min and the reaction was stopped by adding 50 µL 
of stop solution to each well. The ELISA was read using a TECAN Sunrise microplate 
reader (Tecan) at 450nm and analysed with deltaSoft (Tecan). VEGF-A 
concentrations read from the standard curve were multiplied by the dilution factor. 
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Figure 17 Principles of the VEGF-A ELISA (eBioscience) 
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2.5.3. IL-8 ELISA 
IL-8 antigen was detected in cell conditioned media using the human IL8 Quantikine 
ELISA kit (R&D Systems). This ELISA has a standard range from 31.2 to 2000 pg/ml 
according to manufacturer’s instructions. Samples and standards were properly 
diluted with assay diluent, added to the wells and incubated at room temperature for 
2 hours. Test wells were emptied and the plate was washed 4 times with wash buffer, 
the IL-8 conjugate was added to the wells, incubated for 1 hour. Following a washing 
step 200 µl of substrate solution for colour development was applied for 30 min and 
the reaction was stopped by adding 50 µL of stop solution to each well. The ELISA 
was read using a TECAN Sunrise microplate reader (Tecan) at 450nm and analysed 
with deltaSoft (Tecan). IL-8 concentrations read from the standard curve were 
multiplied by the dilution factor. 
 
2.6. Statistical analysis 
Data was compared statistically by t-test and ANOVA. Values of P<0.05 were 
considered significant.  
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3. Results 
 
3.1. Part I: Basal expression of PEDF in human visceral and subcutaneous 
adipocytes.  
 
Human visceral adipocytes derived from human visceral fat expressed 24% more 
mRNA for PEDF than human visceral preadipocytes (Figure 18). Whereas human 
subcutaneous adipocytes derived from human subcutaneous fat expressed just 5% 
more mRNA for PEDF than human subcutaneous preadipocytes. The examined 
visceral and subcutaneous adipose tissue derived from 14 overweight donors (BMI > 
35kg/m²). The differences between PEDF expression in HVAC and HVPAC was 
statistically significant, using t-test for paired samples (p<0.03), one-way ANOVA 
revealed a significant difference (* p<0.01). Differences between PEDF expression in 
HSAC and HSPAC was statistically significant, using one-way ANOVA (* p<0.05). 
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Figure 18 Basal PEDF mRNA expression level in HSADI, HVADI (A), HSPAC and 
HVPAC (B). RNA was prepared from confluent monolayers of untreated HSADI, 
HVADI, HSPAC and HVPAC. PEDF mRNA expression of was analyzed by 
quantitative real-time PCR using glyceraldehyde-3-phosphate dehydrogenase as 
housekeeping gene as described in METHODS AND MATERIALS. Results are 
calculated as x-fold of HVPAC, HSPAC respectively which was set as 1 fold.  Values 
represent means +/- SD of 14 determinations with cells obtained from 14 different 
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3.2. Part II: Effect of inflammatory cytokines on PEDF expression. 
 
 
HSADI, HVADI, HSPAC and HVPAC were treated with different cytokines at the 
indicated concentrations (Table 3) for 4, 24, and 48 h. RNA was prepared from 
confluent monolayers of untreated and treated HSADI, HVADI, HSPAC and HVPAC 
and RT-PCR using specific primer for PEDF and GAPDH as performed as described 
in METHODS AND MATERIALS. 
Treatment of the HSAC, HVAC, HSPAC and HVPAC with the indicated inflammatory 
cytokines (Table 3) for 4, 24 and 48h did not result in a significant change of the 
PEDF mRNA-expression. (Data not shown) 
 
3.3. Part III: Influence of stimulation with PEDF on VEGF production in visceral 
adipocytes.  
 
Effect of PEDF on VEGF expression in visceral adipocytes under normoxic 
conditions.  
 
Under normoxic conditions PEDF treatment increased VEGF expression significantly 
in human visceral adipocytes. If cells were treated with PEDF at a concentration of 





Figure 19 VEGF mRNA expression in human primary adipocytes cultivated under 
normoxic conditions. Confluent monolayers of HVADI were incubated for 24, 48, or 
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72 h in absences or in presence of PEDF at a concentration of 400 ng/ml. Whole 
cells were lysed, mRNA was prepared and analysed by RealTime-PCR with primers 
specific for VEGF and GAPDH as described in METHODS AND MATERIALS. VEGF 
mRNA level was normalized according to the respective GAPDH. mRNA levels are 
given as fold of control which was set as 1-fold. Experiments were performed 3-times 
with cells obtained from 3 different donors and gave similar results. A representative 
experiment is shown. Values represent the mean value +/- SD. (* p<0.5) 
 
Effect of PEDF on VEGF protein production in visceral adipocytes under 
normoxic conditions.  
 
Under normoxic conditions PEDF increased VEGF protein production significantly in 
human visceral adipocytes. If cells were treated with PEDF at a concentration of 400 





Figure 20 Secretion of VEGF in human primary adipocytes cultivated under normoxic 
conditions. Confluent monolayers of HVADI were incubated for 24, 48, or 72 h in 
absences or in presence of PEDF at a concentration of 400 ng/ml. Conditioned 
media were collected and VEGF antigen was determined by ELISA as described in 
MATERIALS AND METHODS. Experiments were performed 3-times with cells 
obtained from 3 different donors and gave similar results. A representative 
experiment is shown.  Values represent the mean value +/- SD (* p<0.005). 
Effect of PEDF on VEGF expression in visceral adipocytes under anoxic 
conditions.  
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Under anoxic conditions PEDF treatment did not influence VEGF expression 
significantly in human visceral adipocytes after 24 and 72h incubations but after 48h 





Figure 21 Expression of VEGF in human primary adipocytes treated with 400 ng/ml 
PEDF for 24, 48, 72 hours cultivated under anoxic conditions.  Confluent monolayers 
of HVADI were incubated for 24, 48, or 72 h in absences or in presence of PEDF at a 
concentration of 400 ng/ml. Whole cells were lysed, mRNA was prepared and 
analysed by RealTime-PCR with primers specific for VEGF and GAPDH as described 
in METHODS AND MATERIALS. Experiments were performed 3-times with cells 
obtained from 3 different donors and gave similar results. A representative 
experiment is shown. VEGF mRNA levels was normalized according to the 
respective GAPDH. mRNA levels are given as fold of control which was set as 1-fold. 
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Effect of PEDF on VEGF protein production in visceral adipocytes under anoxic 
conditions.  
 
Under hypoxic conditions VEGF protein production in control cells was the same as 
in PEDF treated cells. Hypoxia increased VEGF production in control cells and in 
cells treated with PEDF (400 ng/ml) in comparison with PEDF treated cells under 






Figure 22 Secretion of VEGF in human primary adipocytes treated with 400 ng/ml 
PEDF for 24, 48, 72 hours cultivated under normoxic and hypoxic conditions.  
Confluent monolayers of HVADI were incubated for 24, 48, or 72 h in absences or in 
presence of PEDF at a concentration of 400 ng/ml. Conditioned media were collected 
and VEGF antigen was determined by ELISA as described in MATERIALS AND 
METHODS. Experiments were performed 3-times with cells obtained from 3 different 
donors and gave similar results. A representative experiment is shown.  Values 
represent the mean value +/- SD. (* p<0.05) 
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3.4. Part IV: Effect of PEDF on expression and protein level of VEGF in 
HCASMC. 
 
Effect of PEDF on mRNA expression level of VEGF in HCASMC under normoxic 
conditions  
 
When HCASMC under normoxic conditions were treated with PEDF at a 
concentration of 4, 40, 400, 800 ng/ml for time period of 4, 24, 48 and 72h a dose 




Figure 23 Decrease of VEGF mRNA expression by human coronary artery smooth 
muscle cells treated with PEDF is dose and time dependant. Confluent monolayers of 
HCASMC were incubated for 12, 24, 48, or 72 h in absences or in presence of PEDF 
at a concentration of (A) 4, (B) 40, (C) 400 or (D) 800 ng/ml. Whole cells were lysed, 
mRNA was prepared and analysed by RealTime-PCR with primers specific for VEGF 
and GAPDH as described in METHODS AND MATERIALS. Experiments were 
performed 5-times with cells obtained from 5 different donors and gave similar 
results. A representative experiment is shown. VEGF mRNA level was normalized 
according to the respective GAPDH. mRNA levels and are given as fold of control 
witch was set as 1-fold. Values represent the mean value +/- SD (* p<0.01). 
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Effect of PEDF on VEGF protein level in HCASMC under normoxic conditions is 
dose and time dependant. 
 
VEGF ELISA revealed that stimulation of HCASMC with PEDF decreases VEGF 
protein production. When  HCASMC were incubated with PEDF 4 ng/ml under 
normoxic conditions the protein level of VEGF was only slightly diminished, but 
treatment with 40, 400 or 800 ng/ml revealed a significant dose and time dependant 
decrease of VEGF production. If HCASMC were incubated with 40, 400, 800 ng 
PEDF for 48 hours VEGF level was inhibited by 14% (4 ng/ml), 26% (40 ng/ml), 27% 




Figure 24 Effect of PEDF on VEGF protein production level in human coronary artery 
smooth muscle cells is dose-and time-dependent. Control is shown in blue, PEDF 
treated cells in pink. (F=7.60, p<0.05). Confluent monolayers of HCASMC were 
incubated for 12, 24, 48, or 72 h in absences or in presence of PEDF at a 
concentration of (A) 4, (B) 40, (C) 400 or (D) 800 ng/ml. Conditioned media were 
collected and VEGF antigen was determined by ELISA as described in MATERIALS 
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AND METHODS. Experiments were performed 5-times with cells obtained from 5 
different donors and gave similar results. A representative experiment is shown. 
VEGF concentrations are given as fold of control witch was set as 1-fold. Values 
represent the mean value +/- SD (* p<0.05). 
 
 
Effect of PEDF on VEGF protein level in HCASMC under hypoxic conditions. 
 
When HCASMC under hypoxic conditions were treated with PEDF at a concentration 
of 400 ng/ml, VEGF protein production after 48 h was equal to the level in not treated 
cells. However, VEGF protein in both, hypoxic PEDF treated and not treated cells 





Figure 25 Effect of 400 ng PEDF and hypoxia for time periods of 4, 24 and 48h on 
VEGF protein production level in human coronary artery smooth muscle cells. 
Combination of PEDF and hypoxia induced VEGF upregulation. Confluent 
monolayers of HCASMC were incubated for 12, 24 or 48 h in absences or in 
presence of PEDF at a concentration of 400 or ng/ml, under normoxic  (pink) and 
hypoxic (yellow, blue) conditions. Conditioned media were collected and VEGF 
antigen was determined as described in MATERIALS AND METHODS. . 
Experiments were performed 3-times with cells obtained from 3 different donors and 
gave similar results. A representative experiment is shown.  Values represent the 
mean value +/- SD. (* p<0.001) 
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Effect of PEDF on mRNA expression level of IL-8 in HCASMC  
 
When HCASMC were treated with PEDF at a concentration of 400 ng/ml IL-8 mRNA 




Figure 26 Effect of PEDF stimulation on IL-8 expression in HCASMC. Confluent 
monolayers of HCASMC were incubated for 4, 8, 16, 24 or 48 h  in absence or in 
presence of PEDF at a concentration of 400 ng/ml. Whole cells were lysed, mRNA 
was prepared and analysed by RealTime-PCR with primers specific for IL-8 and 
GAPDH as described in METHODS AND MATERIALS. Experiments were performed 
3-times with cells obtained from 3 different donors and gave similar results. A 
representative experiment is shown. IL-8 mRNA level was normalized according to 
the respective GAPDH. mRNA levels are given as fold of control witch was set as 1-
fold. Values represent the mean value +/- SD. (* p<0.05) 
 
 
  46 
Effect of PEDF on IL-8 protein production level in HCASMC 
 
When HCASMC were treated with PEDF at a concentration of 400 ng/ml IL-8 protein 






Figure 27 Effect of PEDF stimulation on IL-8 secretion after 4, 8, 16, 24 and 48 hours 
in HCASMC. Confluent monolayers of HCASMC were incubated for 4, 8, 16, 24 or 48 
h in absences or in presence of PEDF at a concentration of 400 ng/ml. Conditioned 
media were collected and IL-8 antigen was determined by ELISA as described in 
MATERIALS AND METHODS. Experiments were performed 3-times with cells 
obtained from 3 different donors and gave similar results. A representative 
experiment is shown. Values represent the mean value +/- SD. (* p<0.05) 
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3.5. Part V: Effect of PEDF on IL-8 expression and protein production in 
HUVEC. 
 
Effect of PEDF on the IL-8 m RNA level in HUVEC  
 
A significant decrease in IL8 mRNA was observed in HUVEC treated with 400ng/ml 




Figure 28 IL-8 mRNA expression decreases after stimulation with 400ng PEDF for 4, 
8, 24 and 48h in HUVEC. Confluent monolayers of HUVEC were incubated for 4, 8, 
24 or 48 h in absences or in presence of PEDF at a concentration of 400 or ng/ml, 
under normoxic conditions. Whole cells were lysed, mRNA was prepared and 
analysed by RealTime-PCR with primers specific for IL-8 and glyeraldehyd-3-
phosphate (GAPDH) as described in METHODS AND MATERIALS. Experiments 
were performed 3-times with cells obtained from 3 different donors and gave similar 
results. A representative experiment is shown. IL-8 mRNA level was normalized 
according to the respective GAPDH. mRNA level and are given as fold of control 
witch was set as 1-fold. Values represent the mean value +/- SD. (* p<0.05) 
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Effect of PEDF on the IL-8 protein production level in HUVEC  
 
A significant decrease in IL8 protein production was observed in HUVEC treated with 







Figure 29 IL-8 mRNA expression decreases after stimulation with 400ng PEDF for 4, 
8, 24 and 48h in HUVEC. Confluent monolayers of HUVEC were incubated for 4, 8, 
24 or 48 h in absences or in presence of PEDF at a concentration of 400 or ng/ml, 
under normoxic conditions. Conditioned media were collected and IL-8 antigen was 
determined by ELISA as described in MATERIALS AND METHODS. Experiments 
were performed 3-times with cells obtained from 3 different donors and gave similar 
results. A representative experiment is shown. Values represent the mean value +/- 
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4. Discussion 
 
In context of obesity adipose tissue secretes a variety of inflammatory adipokines 
such as IL-6, PAI-1 and TNF- α. A novel adipokine is PEDF, which has been shown 
to be expressed and secreted by adipocytes, differentiated out of human 
mesenchymal stem cells [103] and 3T3-L1 mouse adipocytes [104,105]. Recent 
studies revealed PEDF as one of the most abundant adipokines in supernatant of 
3T3-L1 adipocytes and a significant increase in expression and secretion of PEDF 
during differentiation of human adipocytes was shown. Since Crowe et al. [104] 
demonstrated that PEDF expression in mice correlates with obesity the role of 
adipose tissue in PEDF secretion became evident. Furthermore PEDF protein levels 
are positively regulated with oxygen tension in anoxic cardiac myocytes as well as in 
hypoxic retinal glia cells [37,41]. Famulla et al. could show that in adipocytes hypoxia 
negatively regulates PEDF expression and release [45]. PEDF is involved in many 
physiological and pathological processes of the human organism. However, little is 
known about the regulation of PEDF expression and secretion and its impact on 
angiogenesis. These aspects, which were the focus of the present work, will be 
discussed in the following. 
 
 
Basal PEDF expression in human visceral and subcutaneous preadipocytes 
and adipocytes. 
 
The expression pattern of PEDF during differentiation from human preadipocytes to 
adipocytes is not yet understood in detail. A number of studies point to a decrease in 
PEDF mRNA expression during differentiation in 3T3-L1 cells [84,105], whereas 
other studies showed a differentiation dependant increase of PEDF mRNA in human 
adipocytes [103,106]. Famulla et al showed that in primary human adipocytes 
isolated out of subcutaneous adipose tissue from lean or moderately overweight 
women PEDF secretion and expression increased significantly during differentiation 
process [45]. Crowe et al demonstrated in mice that PEDF secretion in adipose 
tissue correlates with obesity and diabetes [104]. In contrast to other systems we 
didn’t examine whole-tissue PEDF expression which does not account for the 
heterogeneous cellular composition of adipose tissue. The number of dendritic cells 
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increases in adipose tissue with overall body fat mass, which seems to be a source 
of PEDF [107] therefore further processing of adipose tissue is essential for accurate 
results. In our system of in vitro differentiated adipocytes we used subcutaneous and 
visceral preadipocytes isolated out of adipose tissue from patients undergoing gastric 
surgery who had a BMI over 35 kg/m². In the present study PEDF expression in 
human visceral adipocytes, preadipocytes has been characterized in detail. Visceral 
adipocytes expressed 24% more PEDF mRNA than visceral preadipocytes whereas 
subcutaneous adipocytes expressed just 5% more PEDF mRNA than subcutaneous 
preadipocytes. Additionally, two other studies could show that PEDF plasma levels in 
human correlate with obesity [104]. We showed in our study that the PEDF mRNA 
level in subcutaneous preadipocytes and adipocytes differs slightly and that visceral 
adipocytes express a higher PEDF mRNA level than visceral preadipocytes. Famulla 
et al were able to show that subcutaneous adipocytes derived from in lean people 
express significantly more PEDF than subcutaneous preadipocytes, leading to the 
suggestion that in overweight patients subcutaneous preadipocytes are an important 
PEDF source and possible are responsible for the higher PEDF level in obesity [45]. 
 
 
Effect of inflammatory cytokines on PEDF expression  
 
Treatment of the HSAC, HVAC, HSPAC and HVPAC with the inflammatory cytokines 
did not affect PEDF expression in human adipose tissue. Although visceral and 
subcutaneous adipocytes express gp130, the receptor for all gp130 ligands, none of 
the gp130 cytokines used in our study resulted in a significant change in PEDF 




Influence of PEDF on VEGF expression in visceral adipocytes 
 
Modulation of angiogenesis in adipose tissue may constitute a strategy to affect 
obesity [2]. In the present study we demonstrated that PEDF treatment under 
normoxic conditions increases VEGF expression and protein production in human 
visceral adipocytes. This was in contrast to treatment with PEDF under hypoxia 
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where production the of angiogenic stimulator VEGF was not influenced. We 
observed that VEGF protein secretion in visceral adipocytes treated under hypoxic 
conditions was 20% higher than under normoxic conditions. This was in contrast to 
our results Wree et al. recently published that in white adipocytes VEGF expression 
does not change upon hypoxic stimulation [108]. PEDF expression and production by 
adipocytes are elevated in rodent obesity models, also in human overweight patients 
adipose tissue releases PEDF, leading to a higher PEDF level in the bloodstream. 
Adipocytes used for this investigation were isolated from adipose tissue derived from 
overweight patients and therefore probably were exposed to a higher PEDF level. In 
further investigations VEGF expression and production in adipocytes treated with 
PEDF derived from lean patients should be used as comparison. 
 
Effect of PEDF stimulation on VEGF mRNA and protein level in HCASMC  
 
There are many inhibitors and stimulators of angiogenesis and among them, VEGF 
appears as a primary angiogenic stimulator [109]. Several studies showed that PEDF 
can induce differentiation and inhibition of angiogenesis in several tumors and 
disrupts the balance between pro- and anti-angiogenic triggers. Guan et al initially 
demonstrated that PEDF is involved in tumor angiogenesis, by downregulation of 
VEGF and bFGF and enhanced the expression of angiogenic inhibitor 
thrombospondin 1 (TSP-1) [110]. It was demonstrated in mice that substances 
inhibiting the angiogenic effect of VEGF also inhibited the growth of adipose 
tissue.[47] Therefore it seems warranted to acquire more information on the 
expression and functional role of pro- and antiangiogenic factors. In this study, we 
explore whether PEDF as angiogenic factor could be a possible target in the 
regulation of adipose tissue growth. The general aim of this project was to 
comprehend the significance of PEDF for adiposity and angiogenesis. The 
antiangiogenic action of PEDF was identified by Dawson and colleagues [43]. In the 
eye it was demonstrated that PEDF is a major inhibitor of development of vascular 
network counteracting the proangiogenic effect of VEGF [111-114]. Additionally 
antioxidant, anti-inflammatory and anticancer activities of PEDF have been shown 
[48,63,115]. Signalling pathways mediating the broad activities of PEDF have not yet 
been identified. Previous studies demonstrated that VEGF is highly expressed in 
HCASMC. The present study under normoxic conditions identified PEDF as an in 
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vitro inhibitor of proangiogenic factors VEGF in HCASMC, as well on mRNA level as 
on protein production level. We observed a reduction of VEGF production in a dose- 
and time dependant manner. PEDF mediated signalling in HCASMC may lead to 
inhibition of angiogenesis. Interestingly under hypoxic conditions VEGF protein level 
in HCASMC was not influenced by treatment with PEDF. It remains to be elucidated 




Effect of PEDF on IL-8 mRNA expression and secretion in HCASMC and 
HUVEC. 
 
Recently a study from HO et al showed that PEDF induces apoptosis in primary 
macrophages and endothelial cells by increasing PPARγ expression and 
transcriptional activity [58]. Hirsch et al were able to show that PEDF treatment 
inhibits production of IL-8 mRNA and protein in human hormone-refractory cancer 
cells [96]. They demonstrated that PEDF limits IL-8 production through inactivation of 
NFκB and activation of PPARγ. PPAR γ is a nuclear fatty acid receptors with ligand-
dependent transcriptional activity, regulating various aspects of energy homeostasis 
[58]. In the present study we examined the in vitro effect of PEDF on IL-8 production 
in HCASMC and HUVEC and were able to demonstrate a significant decrease in 
mRNA expression and secretion decrease in both cell types. Decreased IL-8 
production is probably involved in the antiangiogenic impact of PEDF. Further 
investigations are needed to test if in HACSMC and HUVEC PPARγ upregulation and 
suppressed NFκB-mediated transcription are the involved pathways in reduced 
production of IL-8 as it was shown in human refractory prostate cancer cells [58,96].  
 
  53 
Conclusion and outlook  
 
The present study confirms the importance of PEDF for various mechanisms of 
angiogenesis. Our study demonstrated that under normoxic conditions PEDF 
increased VEGF mRNA and protein production significantly in human visceral 
adipocytes whereas in HCASMC treated with PEDF a dose and time dependent 
decrease of VEGF mRNA and protein production was observed. These results 
suggest a cell-specific effect of PEDF that needs further investigations. Also, PEDF 
reduces the expression of IL-8, another antiangiogenic factor. IL-8 mRNA and protein 
production was diminished after PEDF treatment as well in HCASMC as in HUVEC. 
Our results indicate that PEDF may play a role in obesity progression. Furthermore in 
adipose tissue PEDF secretion may lead to upregulation of proangiogenic factor 
VEGF. Further research is required to estimate whether blockade of PEDF signalling 
may be a promising tool for obesity therapy.  
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Introduction The proportion of overweight and obese people has increased 
significantly over the last few decades, nowadays one of three adults is overweight 
and one of ten is obese [8]. Overweight and obese patients are at higher risk of 
developing a number of diseases such as cardiovascular diseases such as 
arthrosclerosis,  diabetes mellitus, high blood pressure and cancer and have an 
increased risk of premature mortality [116]. Today overweight and obesity is the fifth 
most frequent cause of death worldwide [8]. Adipose tissue, besides its role in energy 
storage, is now also seen as an important endocrine organ that produces and 
secretes a variety of cytokines, hormones and other proteins [117]. Elevated plasma 
levels of adipose tissue derived factors, called adipokines, are found in obese 
patients and are associated with the development and progression of cardiovascular 
diseases [118,119]. Recently it has been shown that the protein pigment epithelium 
derived factor (PEDF) a 50kDa member of the serpin family is expressed by 
adipocytes. PEDF is a multifunctional protein with antiangiogenic, antithrombotic, 
neuroprotective, antitumorigenic and antiinflammatory properties [103]. It has been 
demonstrated that PEDF is massively expressed in human adipose tissue, 
expression level increases significantly during adipogenesis and  its plasma level is 
elevated in overweight patients [45].  
Aim It is the aim of this project to characterize the possible role of PEDF in obesity 
and to investigate the parakrine effects of PEDF on cell types involved in modulation 
of angiogenesis such as human coronary artery smooth muscle cells (HCASMC) and 
human umbilical vein endothelial cells (HUVEC).  
Methods (I) The first step was to study the regulation of PEDF expression in human 
visceral and subcutaneous preadipocytes and adipocytes. (II) As obesity is 
associated with a generalized inflammatory state we tested whether inflammatory 
mediators affect the expression of PEDF in preadipocytes and adipocytes. (III) As 
anoxia is a critical modulator in various organs and tissues, modulating angiogenesis 
we also studied a possible influence of PEDF in combination with anoxia on the 
expression patterns of adipocytes. (IV) Further on we stimulated human coronary 
artery smooth muscle cells (HCASMC) with PEDF to investigate the inhibition of 
VEGF on RNA and protein level. (V)In addition it was aim of our project to study a 
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possible correlation between PEDF level and Interleukin 8 (IL-8) in HUVEC and 
HCASMC. 
Results PEDF mRNA expression was significantly increased during adipogenesis of 
primary visceral adipocytes. Stimulation of visceral and subcutaneous preadipocytes 
and adipocytes with inflammatory cytokines showed no effect on the PEDF mRNA 
level. Furthermore, PEDF significantly increased VEGF expression and secretion in 
human visceral adipocytes. In visceral adipocytes treated with PEDF under normoxic 
conditions, protein expression was significantly increased in parallel with PEDF 
secretion. In contrast to VEGF increase in adipocytes, VEGF secretion was 
significantly reduced by PEDF in HUVEC and HCASMC. Additionally in HCASMC 
and HUVEC PEDF reduced secretion and expression of IL-8. 
Conclusion PEDF is one of the most abundant secreted cytokines by adipose tissue 
and regulates angiogenic processes by influencing VEGF production in HUVEC, 
HCASMC and HVADI as well as IL-8 secretion in HUVEC and HCASMC. Because of 
these various actions, PEDF seems to be an important adipokine significantly 
involved in the modulation of angiogenesis, obesity progression and obesity-related 
disorders.  
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5.2. Zusammenfassung  
 
Einleitung Der Anteil übergewichtige und adipöser Menschen ist in den 
vergangenen Jahrzehnten stark angestiegen, mittlerweile ist bereits jeder dritte 
Erwachsene übergewichtig und jeder zehnte sogar adipös [8]. Übergewicht und 
Adipositas begünstigen die Entwicklung einer ganzen Reihe von Krankheiten wie 
Herz-Kreislauf-Erkrankungen z.B. Artherosklerose, Diabetes mellitus, Bluthochdruck, 
Krebs und erhöhen das Risiko eines vorzeitigen Todes [116]. Übergewicht und 
Adipositas stellen mittlerweile die fünfthäufigsten Todesursache weltweit dar [8]. 
Fettgewebe ist nicht nur ein Speicherorgan für Energie, sondern wirkt auch als 
aktives endokrines Organ, das eine Vielzahl von Zytokinen, Hormonen und anderen 
Proteinen sezerniert [117]. Die vom Fettgewebe ausgeschütteten Faktoren werden 
Adipokine genannt, kommen im Plasma adipöser Patienten in erhöhter Konzentration 
vor und werden mit der Entstehung und Progression von Herz-Kreislauf-
Erkrankungen in Verbindung gebracht [118,119]. Eines der von Adipozyten 
exprimierten Proteine ist der pigment epithelium derived factor (PEDF), ein 50kDa 
gorßes Mitglied der Serpin Familie. PEDF ist ein pleiotropes Protein mit 
antiangiogenen, antithrombotischen, neuroprotektiven, antitumorigenen und 
antiinflammatorischen Eigenschaften [103]. Erst kürzlich wurde gezeigt, dass PEDF 
im humanen Fettgewebe massiv exprimiert wird, die Expression des PEDF während 
der Adipogenese signifikant ansteigt und dass PEDF im Plasma übergewichtiger 
Menschen in erhöhter Konzentration vorkommt  [45].  
Ziel Ziel dieses Projekt ist es eine mögliche Rolle von PEDF bei Adipositas zu 
charakterisieren und die parakrine Wirkungen von PEDF auf, an der Angiogenese 
beteiligte Zelltypen, wie human coronary artery smooth muscle cells (HCASMC) und 
auf human umbilical vein endothelial cells (HUVEC), zu untersuchen.  
Methoden (I) Zu diesem Zweck wurde die Expression von PEDF in, aus viszeralem 
und subkutanem  Fettgewebe isolierten Präadipozyten und Adipozyten untersucht. 
(II) Zusätzlich wurde untersucht, ob die Expression des PEDF in Präadipozyten und 
Adipozyten durch inflammatorische Zytokine beeinflusst wird. (III) In vivo herrscht im 
Fettgewebe ein entzündliches, mit Sauerstoff minderversorgtes Milieu deshalb wurde 
untersucht ob PEDF unter hypoxische Bedingungen das  Expressionsmuster von 
Adipozyten beeinflusst. (IV) Weiters wurden HCASMC mit PEDF stimuliert um die 
Hemmung der Genexpression von Vascular Endothelial Growth Factor (VEGF) auf 
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RNA- und Proteinebene zu untersuchen. (V) Ebenso sollte untersucht werden ob die 
Expression von IL-8 in HUVEC durch Stimulation mit PEDF beeinflusst wird. 
Ergebnisse Die PEDF Expression ist während der Adipogenese von primären 
visceralen Adipozyten signifikant angestiegen. Die Stimulation von humanen 
visceralen und subkutanen Preadipozyten und Adipozyten mit inflammatorischen 
Zytokinen führte zu keiner signifikanten Veränderung der Expression von PEDF auf 
mRNA Niveau. Expression und Sekretion des VEGF in humanen visceralen 
Adipozyten sind nach Inkubation mit PEDF unter normoxischen Bedingungen 
signifikant angestiegen. Im Gegensatz zum dem Anstieg der VEGF Expression in 
Adipozyten wurde die VEGF Expression und Sekretion  in HUVEC und HCASMC 
durch Behandlung mit PEDF signifikant reduziert. Zusätzlich konnte gezeigt werden, 
dass in HCASMC und HUVEC als Folge von PEDF Stimulation die Expression und 
Sekretion  von IL-8 abfällt.  
Schlussfolgerung PEDF ist eines von Fettgewebe in hohen Konzentrationen 
ausgeschüttetes Zytokin, das an der Regulation der Angiogenese beteiligt ist. In   
HUVEC, HCASMC and HVADI beeinflusst PEDF die Produktion von VEGF und 
außerdem die Sekretion von IL-8 in HUVEC und HCASMC. Durch seine zahlreichen 
Wirkungsweisen könnte der PEDF in der Modulation der Angiogenese von 
Bedeutung sein, ebenso könnte der PEDF eine wichtige Rolle haben bei der 
Progression von Adipositas und von Erkrankungen die im Zusammenhang mit 
Übergewicht stehen. 
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TNF-α   tumour necrosis factor alpha 
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VEGF   vascular endothelial growth factor  
VEGFR  vascular endothelial growth factor receptor 
USF ubiquitous basic helix–loop–helix-leucine zipper transcription 
factor 
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